Form 4: RxSight Executive Ilya Goldshleger Acquires 125,000 Stock Options

Ilya Goldshleger, Co-President and COO of RxSight, Inc., was granted 125,000 stock options on February 27, 2025, according to a Form 4 filing with the SEC.

Summary

• Ilya Goldshleger, Co-President and Chief Operating Officer of RxSight, Inc. (RXST), filed a Form 4 with the SEC on February 27, 2025.
• The filing reports the acquisition of 125,000 stock options.
• These options have an exercise price of $28.21.
• The options vest monthly over a four-year period, starting on February 27, 2025, contingent upon continued service with the company.
• The options expire on February 26, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice, but it does indicate confidence in the company's future.

Positives

• The acquisition of stock options by a high-ranking executive can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedule incentivizes the executive to remain with the company for the long term.

Future Outlook

The vesting schedule suggests a long-term commitment from the executive, aligning their interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the technology and healthcare industries, used to attract and retain talent and align executive incentives with shareholder value.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates